Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24832116 | 0.91 | BLM (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL12417775 | 0.82 | GABRR1 (0.45) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL28044406 | 0.82 | GABRR1 (0.45) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL5139179 | 0.81 | GABRR1 (0.72) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL3753790 | 0.80 | GABRR1 (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL27286922 | 0.80 | GABRR1 (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL17308179 | 0.78 | GABRR1 (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL28466762 | 0.78 | GABRR1 (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL1642423 | 0.78 | GABRR1 (0.34) | GABRR1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL28470872 | 0.78 | GABRR1 (0.50) | GABRR1CYP1A2BLMACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116576-A | Quinolizinone compound and preparation method thereof | 北京师范大学 | 2020-05-08 | — | — | CN | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| EP-1881988-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | GABRR1 257/4885CYP1A2 1418/4885BLM 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.